BriaCell Therapeutics’ (BCTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock.

BriaCell Therapeutics Stock Up 27.7 %

Shares of BCTX stock opened at $5.35 on Tuesday. The company has a market capitalization of $19.84 million, a price-to-earnings ratio of -0.40 and a beta of 1.34. BriaCell Therapeutics has a 12-month low of $3.00 and a 12-month high of $36.60. The firm has a fifty day moving average of $4.05 and a 200-day moving average of $7.75.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, March 17th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.39). On average, equities analysts expect that BriaCell Therapeutics will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in BriaCell Therapeutics in the 4th quarter valued at $27,000. Cantor Fitzgerald L. P. acquired a new stake in shares of BriaCell Therapeutics in the fourth quarter valued at about $32,000. Finally, Vontobel Holding Ltd. raised its holdings in BriaCell Therapeutics by 37.5% during the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after acquiring an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.